|
LIVE WEBINAR: Tuesday, January 4, 2022, 5:00 PM – 6:00 PM Eastern Time (ET)
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology A Multitumor CME/MOC-Accredited Live Webinar Series
Join us on Tuesday, January 4th for this CME/MOC-accredited webinar Faculty
John P Leonard, MD Richard T Silver Distinguished Professor of Hematology and Medical Oncology Senior Associate Dean for Innovation and Initiatives Executive Vice Chair, Joan and Sanford I Weill Department of Medicine Weill Cornell Medicine New York, New York
Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group BC Cancer Centre for Lymphoid Cancer Clinical Professor of Medicine Division of Medical Oncology University of British Columbia Associate Editor, Blood Vancouver, British Columbia, Canada Moderator Neil Love, MD Research To Practice Miami, Florida Tuesday, January 4, 2022 Topics to Be Discussed
Target Audience Learning Objectives
CE Credit Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Content Validation and Disclosures FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Leonard — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Miltenyi Biotec, Mustang Bio, Regeneron Pharmaceuticals Inc, Second Genome, Sutro Biopharma; Contracted Research: Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group. Dr Sehn — Advisory Committee and Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Apobiologix, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lundbeck, Merck, MorphoSys, Novartis, Pfizer Inc, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Seagen Inc, Takeda Pharmaceuticals USA Inc, Teva Oncology, Verastem Inc; Contracted Research: Teva Oncology. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |